Written and medically reviewed by: Assoc. Prof. Cengiz Dibekoğlu, MD, General SurgeryLast updated:
GIST and Neuroendocrine Tumors
Pathology-driven rare tumors
GIST and NET are not “stomach cancer packages.”
Gastrointestinal stromal tumors (GIST) and neuroendocrine tumors (NET) need pathology, mutation or grade data, and organ-specific planning. They are not managed with a generic gastric-adenocarcinoma checklist. Selected small, low-risk gastric GIST may be surveilled; PDGFRA D842V changes tyrosine-kinase expectations including imatinib resistance. NET versus neuroendocrine carcinoma (NEC) separation is critical — biology and urgency differ. Surgery, TKIs, somatostatin analogs, and peptide-receptor therapies enter only after the report answers the right questions.
Educational schematic. Some structures may be simplified or emphasized for clarity; not an exact anatomical depiction.
© Cengiz Dibekoğlu — illustrative; not for unauthorized use
Figure summary
- Hero figure: GIST and neuroendocrine tumor overview.
- Related figures support diagnosis, staging language, and treatment pathway concepts.
Educational figures
Tap a figure to enlarge. These English illustrations mirror the Turkish hub gallery for this condition.
GIST Educational schematic. Some structures may be simplified or emphasized for clarity; not an exact anatomical depiction.
© Cengiz Dibekoğlu — illustrative; not for unauthorized use
NET Educational schematic. Some structures may be simplified or emphasized for clarity; not an exact anatomical depiction.
© Cengiz Dibekoğlu — illustrative; not for unauthorized use
Diagnosis Educational schematic. Some structures may be simplified or emphasized for clarity; not an exact anatomical depiction.
© Cengiz Dibekoğlu — illustrative; not for unauthorized use
Treatment Educational schematic. Some structures may be simplified or emphasized for clarity; not an exact anatomical depiction.
© Cengiz Dibekoğlu — illustrative; not for unauthorized use
Pathology first
Do not lock major therapy without the report.
GIST mutations
PDGFRA D842V changes TKI expectations.
NET vs NEC
Different biology and urgency.
Selective surveillance
Only for selected small low-risk gastric GIST.
What to know
- Key note inside
GIST surveillance limits
Surveillance is limited to selected small, especially gastric, non–high-risk lesions. Size, site, and mitotic features decide.
- Key note inside
Mutation-aware TKI talk
Note: D842V is not a standard imatinib success story.KIT and PDGFRA context matter. Assuming imatinib works for PDGFRA D842V is a planning error.
NET localization and grade
Grade, Ki-67, organ, size, and behavior individualize care for localized G1–G2 disease.
- Key note inside
NET versus NEC
If the report does not clearly separate NET from NEC, therapy should not be locked. NEC behaves differently and often more urgently.
Surgery still has a role
Resectable primary disease and selected metastases are discussed with mutation/grade context — not postponed forever for “rare tumor mystique.”
What happens next
GIST — explained for shared decision-making
- 1
Gastrointestinal Stromal Tumor (GIST)
GIST — explained for shared decision-making
Read this chapter - 2
Neuroendocrine Tumors (NET)
NET — explained for shared decision-making
Read this chapter - 3
GIST & NET Diagnosis
How clinicians confirm the problem and stage the next steps
Read this chapter - 4
GIST & NET Treatment
How treatment options are matched to risk, stage, and goals
Read this chapter
Appointment / info
Pathology with IHC and mutation details is the most useful document you can bring.
This page is for education. It is not medical advice and does not replace a visit with your physician.
Medical editor: Assoc. Prof. Cengiz Dibekoğlu, MD · English patient-education hub.